Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. (BOSS-002)

March 22, 2024 updated by: Novatek Pharmaceuticals

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase IIa/IIb Study to Evaluate the Safety, Tolerability, and Efficacy of NP-101 in Treating High-Risk Participants Who Have Tested Positive for Novel Coronavirus 2019.

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19. The main question[s] it aims to answer are:

  • To evaluate the safety of NP-101, as well as establish the maximum tolerated dose in high risk Covid-19 positive patients.

Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items]. If there is a comparison group: Researchers will compare [insert groups] to see if [insert effects].

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a Phase IIa/IIb multicenter, interventional, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of NP-101 in outpatient high-risk COVID-19 positive participants. Blinding roles: Participants, Investigators and Sponsor

The study is comprised of two parts (Phase IIa and Phase IIb) and four cohorts. The first part of the trial (IIa) involves three cohorts and is a dose escalation study designed to select the maximum tolerated dose for use in the second part (IIb) of the study. In the dose escalation (Phase IIa) portion of the trial (n= 60), qualified participants will be enrolled in a parallel dose escalation design and randomized in a 3:1 [active+best supportive care (BSC):placebo+BSC]ratio to one of three cohorts of 20 participants each (15 active +BSC, 5 placebo + BSC). Cohort 1 (15 participants taking 600 mg capsules for a total daily dose of 3 grams of NP-101 plus BSC and 5 participants taking placebo plus BSC), and Cohort 2 (15 participants taking 600 mg capsules for a total daily dose of 4.8 g of NP-101+ BSC and 5 participants taking placebo plus BSC will run concurrently since acceptable safety data for the 3 g dose was obtained in an earlier phase II study.

Cohort 1 will receive either 3 g Total Daily Dose (TDD) of NP-101 + BSC or Placebo+ BSC, Cohort 2 will receive either 4.8 g TDD of NP-101 +BSC or placebo + BSC) and Cohort 3 (15 participants taking 600 mg capsules for a total daily dose of 6 g of NP-101 + BSC and 5 participants taking placebo plus BSC.) Safety will be evaluated according to the terms of the Statistical Analysis Plan (SAP). In the second portion of the trial (Phase IIb), Participants enrolled in Cohort 4 (n= 248) will be randomized in a ratio of 1:1 (active+BSC : placebo+BSC) and will receive the Maximum Tolerated Daily Dose (MTDD) as determined by the parameters set by the SAP and approved by the pharmacovigilance team.

Study Type

Interventional

Enrollment (Estimated)

308

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Florida
      • Miami, Florida, United States, 33142
        • Recruiting
        • L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator
        • Contact:
    • Illinois
      • Berwyn, Illinois, United States, 60402
    • Texas
      • Houston, Texas, United States, 77074
        • Recruiting
        • Clinical Trial Network
        • Contact:
        • Principal Investigator:
          • Susan Vogel, MD
      • Pearland, Texas, United States, 77584
        • Recruiting
        • Pearland Family Wellness Clinic
        • Contact:
        • Principal Investigator:
          • Enas Kaseb, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • A resting SpO2 of >93% on room air.
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 and over, presenting with mild to moderate clinical symptoms of Covid- 19 infection (per FDA guidance - see appendix 3) with symptom onset within 5 days prior to the day of randomization
  • Positive COVID-19 infection confirmed by RT-PCR within the last 5 days of the day of randomization
  • A score of ≥ 2 (moderate) on a minimum of 1 symptom on the PRO Symptom Survey on the day of randomization
  • Ability to take oral medication and be willing to adhere to the dosing regimen (Twice a day - BID for 14 days)
  • For females of reproductive potential: negative pregnancy test at screening and use of highly effective contraception method during study participation and for an additional 4 weeks after the end of study drug administration
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of study drug administration
  • Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration

  • To be considered high risk, participants should have at least one of the following conditions:

    • age ≥60 years;
    • active cancer
    • chronic kidney disease;
    • chronic lung disease including COPD
    • Obesity (BMI ≥30)
    • serious heart conditions [heart failure, coronary artery disease, or cardiomyopathies];
    • Diabetes (type 1 or type 2)
    • Immunocompromised state (weakened immune system or autoimmune diseases)
    • Chronic liver disease
    • Cystic fibrosis
    • HIV infection
    • Smoking, current or former
    • Sickle cell disease or thalassemia
    • Solid organ or blood stem cell transplant
    • Stroke or cerebrovascular disease

Exclusion Criteria:

  • Current or recent (within 4 weeks) treatment with any corticosteroids; however, inhaled steroids, which are used to treat acute or chronic bronchial inflammation, will be permitted
  • Severe Covid-19 symptoms (severe per FDA classification - see appendix 3)
  • Requires immediate admission to hospital for any reason
  • Pregnancy or lactation
  • Known allergic reactions to components of black seed oil or thymoquinone
  • Treatment with another investigational drug or other investigational intervention within 2 weeks of study start and throughout study duration.

  • Significant hepatic disease (ALT/AST> 4 times the ULN); any laboratory parameter >/= 4 times the ULN or platelet count <100,000/µ L or neutrophilic granulocyte absolute count

    o <500/mm3

  • History of moderate to severe CKD, (i.e. on hemodialysis or has an estimated glomerular filtration rate less than 45mL/min) at the time of enrollment
  • Participants with inflammatory bowel disease (such as Crohn's) that could affect the intestinal absorption of NP-101 enteric coated capsules.
  • Known uncontrolled HIV (with a recent viral load > 50 copies/mL or CD4<200 cells/mm3 or known active uncontrolled Hepatitis B (defined as HBsAg-positive or detectable HBV DNA viral load) or known active Hepatitis C (defined as detectable HCV RNA viral load) infection
  • Influenza diagnosis (confirmed by testing) during screening or within prior 14 days
  • Any uncontrolled condition(s) or diagnosis, both physical or psychological, or physical exam finding that precludes participation, as per investigator
  • Current treatment with CYP2C9 substrates (see Appendix 5)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Drug Treatment
Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.
Drug: NP-101
NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
Other Names:
  • TQ Formula
Placebo Comparator: Placebo
As above, except dosed with matching placebo capsules.
Other: Placebo
Identical placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Tolerability of NP-101 vs Placebo (Phase IIa and IIb)
Time Frame: Through Day 45
Evaluation of the number of overall adverse events, related adverse reactions, adverse events leading to d/c of study drug and hospitalizations or death.
Through Day 45
Time to Sustained Clinical Recovery
Time Frame: Through Day 5
Measurement of the difference of SCR rates on Day 5 in patients taking the MTDD of NP-101 vs Placebo.
Through Day 5
Establishment of MTDD
Time Frame: Fourteen days per dose (Phase IIA Only)
Number of DLTS (Dose Limiting Toxicities) in the NP-101 arm at each dose compared to placebo and the safety threshold
Fourteen days per dose (Phase IIA Only)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Sustained Clinical Recovery
Time Frame: Through Day 5
Measurement of the difference of SCR rates on Day 5 in patients taking the MTDD of NP-101 vs Placebo.
Through Day 5

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novatek Pharmaceuticals

Investigators

  • Study Director: Ahmed Kaseb, MD, Novatek Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 22, 2023

Primary Completion (Estimated)

October 22, 2024

Study Completion (Estimated)

October 22, 2024

Study Registration Dates

First Submitted

March 23, 2023

First Submitted That Met QC Criteria

March 23, 2023

First Posted (Actual)

March 27, 2023

Study Record Updates

Last Update Posted (Actual)

March 26, 2024

Last Update Submitted That Met QC Criteria

March 22, 2024

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BOSS-Covid-19-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe